CML Pediatric ITK Response According to Molecular Identification at Diagnosis

Treatment of chronic myeloid leukemia (CML) has been revolutionized by tyrosine kinase inhibitor (TKI). Nevertheless, case of failure and suboptimal response are still observed even in children. Pediatric CML is a rare disease and differs from adult in terms of disease presentation and treatment response underlying a likely different CML biology. Molecular mechanisms that induce resistance to TKI are still poorly characterized except mutations in the tyrosine kinase domain of BCR::ABL1. We propose to search for a molecular signature to predict the response to TKI in the pediatric population.

NCT Number	NCT05605379
Lead Sponsor	University Hospital, Bordeaux
Conditions	Chronic Myeloid Leukemia
Enrollment	88 participants
Start Date	2023-02-27
Primary Completion	2025-01 (estimated)
Study Completion	2025-03 (estimated)
Updated on ClinicalTrials.gov	2024-08-14